The ESMO Virtual Congress 2020, September 19-21, will present promising new developments aimed at improving cancer patient care.  In response to the needs of the moment, the scientific program will include a dedicated COVID-19 and cancer research track.

ESMO 2020 will offer: live streaming of sessions; a live chat and Q&A function; pre-recorded sessions on demand; industry satellite symposia on demand; e-posters; a virtual exhibition; live chat with exhibitors; other post-event resources. While it is likely that many of the networking opportunities will be lost, there are still plenty of clinical highlights.

Pivotal trial results and late-breaking abstracts once again come out swinging against NSCLC and ES-SCLC lung cancer.

Key presentations include:

  • Exploratory data from the ADAURA Phase III Trial showing further support for the unprecedented patient benefit of osimertinib (Tagrisso)in the adjuvant treatment of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) also presented in a Presidential Symposium
  • Data from the PACIFIC Phase III Trial in unresectable Stage III NSCLC and the CASPIAN Phase III trial in extensive-stage small-cell lung cancer (ES-SCLC), two late-breaking presentations strengthening the Company’s leadership in the treatment of lung cancer.
  • RELAY trial results look at outcomes by EGFR mutation type in previously untreated EGFR-mutated  metastatic NSCLC patients with ramucirumab in combination with erlotinib for the first-line treatment of people with metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
  • Patient-reported outcomes on health-related quality of life from the Phase 3 CheckMate–9LA trial of nivolumab (Opdivo) plus ipilimumab (Yervoy) in combination with two cycles of chemotherapy versus chemotherapy in patients with metastatic advanced NSCLC.

 

Stayed tuned as Physician’s Weekly keeps you updated on data being presented this year that will no-doubt reshape clinical practice in the months and years ahead. 

More information visit: ESMO Virtual Congress 2020

Author